OPENING: THE TONY HUGE LENS

Why Everything You’ve Read About Nootropics Is Incomplete

There are two kinds of nootropics content. The first kind lives in academic journals and mainstream health publications. It’s cautious, heavily footnoted, and perpetually three to seven years behind what people are actually experiencing. It won’t tell you what dose actually works, it won’t mention the compounds that aren’t approved, and it will never admit that a peptide discovered by Soviet researchers decades ago might outperform the $80 supplement that just got a clinical trial funded by the company selling it.

The second kind lives in forums, Telegram groups, and the personal logs of self-experimenters. It’s raw, often reckless, occasionally brilliant, and has no context. Someone reports that 9-Me-BC changed their life. Someone else says it gave them a headache for a week. No mechanism. No controls. No comparison to the established baseline.

You’ve been forced to choose between incomplete and incomplete.

This report doesn’t make you choose. Every edition pulls from both — clinical literature and underground intelligence — and runs it through one filter: what actually moves the needle, evaluated honestly, with no commercial agenda dictating the rankings.

The name says everything. Better Than Natural. That’s the premise. The brain you were born with is the starting point, not the ceiling. Nature gave you baseline dopamine, baseline acetylcholine, baseline neuroplasticity. The compounds in this report exist because someone, somewhere, decided that baseline wasn’t enough.

Most of them were right.

The Tony Huge Laws of Biochemistry Physics — Applied to Nootropics

These laws come directly from the Better Than Natural and Enhanced framework — distilled from years of personal experimentation, thousands of blood panels, and watching hundreds of people transform. They are not theories. Every protocol and ranking in this report is evaluated through them.

Law 1: A Day Natural Is a Day Wasted

Every day without optimizing your biochemical environment is unrealized potential. The natural state of the human brain in 2026 is not some pristine baseline worth protecting — your water has microplastics, your food has pesticides, your dopamine system is under constant engineered attack. You’re already chemical. The only question is whether you’re using chemistry intelligently or letting random environmental chemistry use you.

Applied to nootropics: there is no neutral. You’re either optimizing or you’re declining.

Law 2: The Law of Extreme Homeostasis — Pendulum Theory

Your brain is a survival machine. It doesn’t care about your goals. It cares about maintaining the status quo. Homeostasis is why nootropic tolerance develops, why stacks stop working at month three, why you plateau.

The solution is not to push harder in one direction. It’s to swing the pendulum deliberately in both directions — upregulate aggressively, then cycle off and let the system reset. Your brain can’t establish homeostasis against a moving target. The cycling protocols in this report are not optional.

Law 3: The Law of Pathways — The Biohacking Matrix

Every cognitive goal breaks down into specific biochemical pathways. The Rational Biohacker identifies pathways first, then selects interventions by mechanism of action. Three tiers: lifestyle first, supplements second, research chemicals third. Within each tier: prioritization, limiting factors, synergy, and state of the body.

The endless internet debate about the “best single nootropic” is asking the wrong question. The multi-pathway stack is not a preference — it’s what Law 3 requires.

Law 4: Every Biological Problem Has a Chemical Solution

For every biological problem there exists a molecule that addresses it. Self-awareness comes first: blood work, cognitive assessments, honest performance tracking. Then apply the Worth the Energy Test — calculate energy cost plus financial cost versus benefit, compare to every alternative. Rank them. Start from the top.

Law 5: The Law of Utility vs. Toxicity — Every Compound Is a Tool

Every compound is both medicine and poison. Dose makes the distinction. Minimum effective dosage. Law of diminishing returns. Tolerance management through cycling, not escalation. Side effect aggregation — when running multiple compounds, side effects stack even when each individual compound is dosed conservatively.

Law 6: Human Modes — The Right Chemistry at the Right Time

Your brain operates in distinct biochemical modes: wake, work, training, recovery, sleep. Each has a specific signature. Stack architecture is not just about what compounds — it’s about when. When you align interventions with modes, every element plays at the right moment.

A Note on the Underground Lead Time

If a compound is in a published clinical trial, biohackers were running it three to seven years ago. This is a consistent pattern across essentially every meaningful nootropic of the last thirty years. Piracetam, Noopept, Semax, Selank, Spermidine, Magnesium L-Threonate — all discovered by the underground first, confirmed by clinical research later.

This has one practical implication: waiting for peer-reviewed consensus means you are always behind. The clinical half of this report validates what the frontier half already found. Together they tell a complete story. Neither tells it alone.

PART ONE: CLINICAL RESEARCH UPDATES — Q1 2026

What the published science actually said this quarter — and what it means in practice

1.1 The Miracle Molecules Update

New Research on Established Compounds — Are They Still the Best Options?

Every quarter brings new excitement over newly studied compounds. This section answers the critical question first: does the new data actually beat what we already have? In Q1 2026, the established compounds held their positions.

Racetams — The Unchanged Benchmark: New mechanistic data adds further detail to piracetam’s AMPA glutamate receptor modulation, confirming effects on membrane fluidity and receptor sensitivity are more significant than the acetylcholine narrative that dominated early research.

Noopept — Delivery Method Is Everything: Updated bioavailability data confirms sublingual administration produces significantly higher peak levels than oral. Most people who report weak noopept effects were taking it orally.

Alpha-GPC vs CDP-Choline — Law 3 Applies: They are complementary pathways, not competing options. Moderate doses of both outperform high dose of either.

Lion’s Mane — NGF Research Gets Stronger: Q1 2026 moved this from “promising” to “validated” in the neuroplasticity category. Six to twelve weeks is where the structural benefits accumulate.

Bacopa Monnieri: Extended data confirms the 12-week pattern. Memory consolidation benefits are real, consistent, and require patience.

1.2 New Compounds Getting Clinical Attention

5-Amino-1MQ — The NAD+ Approach Gets Corrected: Works by inhibiting NNMT (the enzyme that degrades NAD+). Instead of flooding the system with precursors and hoping they convert, you reduce degradation. Mechanistically superior to NMN/NR for the same goal.

Magnesium L-Threonate — RCT Confirms What the Underground Already Knew: Another solid RCT in Q1 confirming superior brain magnesium elevation. Underground lead time: roughly 12 years.

Spermidine — Autophagy Research Gets Clinical Legs: New data connects spermidine to measurable memory improvements via autophagy-mediated clearance. Underground lead time: 5-7 years.

Bromantane — The Compound That Shouldn’t Be Unknown: Dopaminergic enhancement through upregulation of the enzymes that synthesize dopamine. Combined with adaptogenic properties, it occupies a category almost nothing else does.

1.3 FDA & Regulatory Watch

Continued pressure on compounding pharmacies, modest practical effect on access so far. The longer-term trajectory is a continued narrowing of the easy-access window. Tony Huge and Enhanced paved the way for the Enhanced Games’ growing legitimacy, furthering the cultural framing shift of cognitive and physical enhancement.

1.4 The Hype Cycle Correction

Proprietary Blends: Prevent verifying whether therapeutic doses are present. Multi-mushroom blends are the clearest example — Lion’s Mane alone at therapeutic dose does more than most blends across all their combined ingredients.

The Recency Bias Tax: Several newly marketed compounds were benchmarked against a well-constructed foundation stack. None exceeded the baseline. New does not mean better.

1.5 The Viral Hype Audit

Instagram Said It Was Revolutionary. Here’s the Reality.

Methylene Blue — A Correction to the Correction

Coach Trevor and Tony Huge were publicly using methylene blue around 2016 — years before Joe Rogan mentioned it, years before RFK Jr. appeared with it. Underground lead time: approximately ten years.

At low doses (10mg daily), it acts as an electron carrier in the mitochondrial respiratory chain, supporting cellular energy production at the neural level. The compound is inexpensive, well-tolerated, and adds a mitochondrial support pathway that complements the rest of the stack.

Critical Warning: Methylene blue inhibits MAO. Combining it with serotonergic drugs — especially MDMA — creates genuine risk of serotonin syndrome with potentially fatal consequences. At 10mg daily the risk is manageable. At higher doses, the interaction risk becomes a serious medical concern. Pharmaceutical-grade only.

Verdict: Belongs in the stack at low dose. Not the revolutionary brain compound viral content claims. A useful, inexpensive mitochondrial tool at the right dose.

Cerebrolysin — The Injectable “Gold Standard” That Isn’t

Requires intramuscular or intravenous injection. The mechanism — mimicking BDNF and NGF — is already addressed through multiple oral and intranasal compounds in the current stack: Semax, Lion’s Mane, Noopept, 4-DMAE-7,8-DHF, NSI-189.

Verdict: Earns its reputation in neurological recovery. For healthy cognitive enhancement, does not pass the Worth the Energy Test against the existing stack.

Ashwagandha — Category Correction

A good adaptogen with real cortisol-modulating effects. But the mechanism is restorative, not enhancing. It helps you get back to baseline when stress has degraded it. It does not push you above baseline.

Verdict: Belongs in a stress-management protocol. Not a nootropic in the meaningful sense.

Alpha Brain and the Premium Blend Problem

The honest comparison: Alpha-GPC alone at 300mg, Lion’s Mane alone at 1000mg, and Bacopa alone at 300mg each individually costs less than Alpha Brain and delivers verifiable therapeutic doses of better-characterized compounds.

Verdict: Buy the components.

Creatine — The Nootropic the Market Slept On

Consistent data on brain energy support via phosphocreatine buffering in neural tissue, particularly under cognitive load and sleep deprivation. Cheap, widely available, well-characterized for safety.

Verdict: Belongs on every beginner’s list. Mainstream sports framing has obscured a legitimate cognitive application.

PART TWO: UNDERGROUND INTELLIGENCE REPORT

What the frontier researchers, self-experimenters, and biohacker networks are actually running

2.1 Tony Huge’s Personal Nootropics Protocol — April 2026

This is the actual current stack. Every compound passed the Worth the Energy Test and fits the multi-pathway architecture Law 3 requires.

Daily Foundation

• Lion’s Mane (fruiting body, standardized, high hericenone content) — NGF/BDNF upregulation, structural neuroplasticity, long-cycle benefit
• Magnesium L-Threonate — brain magnesium elevation, synaptic density, sleep architecture support
• Methylfolate — methyl donor supporting neurotransmitter synthesis; essential for MTHFR variants and broadly underused

NAD+ Pathway

• 5-Amino-1MQ — NNMT inhibition for superior intracellular NAD+ elevation. Replaced NMN/NR this cycle.

Cognitive Performance Layer

• Noopept (sublingual) — BDNF/NGF upregulation + AMPA modulation; oral bioavailability is inadequate
• NSI-189 — hippocampal neurogenesis; one of the few compounds targeting physical growth of hippocampal tissue
• 4-DMAE-7,8-DHF — direct TrkB agonist; activates the BDNF receptor without requiring BDNF itself

Dopaminergic Layer

• Bromantane — dopamine synthesis upregulation at the enzyme level; on-demand, not daily
• Tyrosine — dopamine precursor loading; contextual use on high-demand days
• 9-Me-BC — dopamine synthesis through complementary mechanism to Bromantane; careful frequency management

Peptide Layer

• Semax (intranasal) — BDNF upregulation, dopaminergic enhancement, clean motivational effect without stimulant drawbacks
• Selank (intranasal) — anxiolytic-nootropic; GABA modulation without tolerance, memory consolidation support

Advanced Layer

• Dihexa — synaptogenesis promoter; among the most potent compounds available. Experimental territory.
• FL-Modafinil — eugeroic wakefulness; on-demand for specific high-demand situations only

2.2 What the Underground Is Running Right Now

Compounds 3–7 Years Ahead of Clinical Research

Semax + Selank — The Russian Peptide Stack

Synthetic peptides developed by the Institute of Molecular Genetics in Moscow, in clinical use in Russia for decades. Semax upregulates BDNF and enhances dopaminergic transmission — clean motivation without jitteriness, crash, or comedown. Selank modulates GABA-A without tolerance and dependency. Together: anxiety, focus, motivation, and BDNF upregulation simultaneously. Intranasal delivery is non-negotiable.

NSI-189 — Growing More Brain

Stimulates hippocampal neurogenesis — actual physical growth of new hippocampal tissue. Most users report nothing for weeks two to four, then significant improvement in verbal fluency and cognitive clarity from weeks four through eight, with persistent improvements after cycling off.

4-DMAE-7,8-DHF — Closing the BDNF Loop

Directly activates TrkB, the primary BDNF receptor, without requiring BDNF itself. Closes the loop between upstream BDNF production and receptor-level activation. Acts as a multiplier for every other BDNF-upregulating compound in the stack.

9-Me-BC — Expanding the Dopamine Pool

Upregulates the enzymes responsible for dopamine synthesis — increasing capacity rather than releasing stored dopamine. Users report gradual improvement in baseline motivation with no tolerance development. Zero clinical trials in humans. Careful frequency management essential.

Dihexa — The Most Potent Synaptogenic Compound

Promotes synaptogenesis at potency levels that dwarf other compounds. Consistent user reports: measurable and lasting improvements in processing speed and complex cognition. No long-term human safety data. Genuinely experimental territory.

2.3 The Multi-Pathway Analysis

BDNF Production + Receptor Activation Stack: Lion’s Mane + Noopept (sublingual) + Semax + 4-DMAE-7,8-DHF. Covering production, alternative production pathway, receptor modulation, and receptor activation simultaneously. The result is multiplicative, not additive.

The Dopaminergic Architecture: Bromantane + 9-Me-BC + Tyrosine + Methylfolate. Three different intervention points in dopamine synthesis. None release existing dopamine. All increase the system’s capacity to produce it.

Neuroplasticity and Structure: NSI-189 + Lion’s Mane + Magnesium L-Threonate + Bacopa. Six to twelve week minimum for structural benefits.

Anxiety-Cognitive Dual Protocol: Selank + Bacopa + L-Theanine. Running this as a foundation before adding activating compounds ensures the performance architecture isn’t undermined by stress chemistry.

2.5 Community Data Aggregation

Consistent Positive: Lion’s Mane at high dose over 8+ weeks, Semax intranasal, Selank, Magnesium L-Threonate before sleep, Bacopa at 8+ weeks, 5-Amino-1MQ, NSI-189 (delayed onset then significant verbal fluency improvement).

Inconsistent Results: Noopept (delivery method accounts for variance), 9-Me-BC (product quality + frequency), Bromantane (tolerance with daily use), Dihexa (quality variability + individual response).

Genetic Note: COMT gene variants significantly affect response to dopaminergic compounds. Know your COMT status before building the dopaminergic architecture.

PART THREE: THE INTEGRATED PROTOCOLS

Where clinical research and underground intelligence converge

3.1 The Better Than Natural Nootropics Hierarchy — April 2026

3.2 Goal-Specific Protocol Recommendations

Cognitive Performance Under High Demand: Piracetam + Alpha-GPC + Aniracetam + Semax + Bromantane (on-demand) + FL-Modafinil (on-demand). Law 6 — this is a work-mode stack.

Neuroplasticity and Long-Term Learning: Lion’s Mane + Noopept + Semax + 4-DMAE-7,8-DHF + NSI-189 + Bacopa + Magnesium L-Threonate. Six to twelve week minimum.

Mood, Motivation, and Sustained Drive: Bromantane + 9-Me-BC + Tyrosine + Methylfolate + 5-Amino-1MQ. Dopamine synthesis capacity expanded through multiple mechanisms simultaneously.

Neuroprotection and Long-Term Brain Health: Bacopa + Lion’s Mane + Spermidine + 5-Amino-1MQ + Magnesium L-Threonate. The anti-aging approach to the brain.

Recovery From Cognitive Burnout: Selank + Bacopa + Magnesium L-Threonate + Lion’s Mane + Methylfolate. Remove stimulants. Support repair and consolidation pathways.

3.3 The Beginner, Intermediate, and Advanced Stacks

3.4 What Got Dropped This Quarter — And Why

NMN and NR as Primary NAD+ Strategy — Replaced by 5-Amino-1MQ. Degradation-inhibition over precursor loading.

Racetam Rotation — Currently on cycle break. Returning Q2 2026 with fresh baseline.

Daily FL-Modafinil — Moved to on-demand after observing next-day creative dulling.

INTERESTING PERSPECTIVES

While this report focuses on the direct biochemical pathways, the frontier of cognitive enhancement is also being explored through unconventional lenses. These perspectives don’t replace the core nootropics stack, but they offer alternative angles for the advanced biohacker.

• The “Second Brain” Connection: Emerging research continues to explore the gut-brain axis, suggesting that compounds which modulate the microbiome (like certain polyphenols or prebiotics) may indirectly influence neuroinflammation and neurotransmitter production, creating a foundational layer for nootropic efficacy. This is a long-term, systemic play, not a direct cognitive stimulant.
• Bioelectric Nootropics: A fringe but fascinating area looks at compounds that may influence the brain’s endogenous electrical fields or ion channel function beyond simple electrolyte balance. The mechanism of Magnesium L-Threonate on synaptic plasticity touches on this, but more targeted research is needed.
• Contrarian Take on “Natural” Nootropics: The push for “all-natural” stacks often ignores potency and bioavailability. A high-dose, standardized extract like Lion’s Mane is a pharmaceutical-grade intervention derived from nature, not a gentle supplement. The distinction between source and effect is critical.
• The Entropic Brain Hypothesis & Nootropics: Some theorists propose that certain psychedelics (like microdosed psilocybin) and potentially nootropics that enhance connectivity (like Dihexa) work by temporarily increasing the entropy or complexity of brain networks, potentially breaking rigid thought patterns. This is highly speculative but frames enhancement not as simple “stimulation” but as a change in network dynamics.
• Cross-Domain Synergy: The most potent “nootropic” effect often comes from combining biochemical tools with behavioral protocols like non-sleep deep rest (NSDR), deliberate cold exposure, or specific learning techniques. The chemical stack prepares the neurochemical environment, but the behavioral input dictates what is built with that material. This is a core principle of the Tony Huge Laws of Biochemistry Physics — chemistry enables, but application determines the outcome.

CLOSING: THE BETTER THAN NATURAL DOCTRINE APPLIED

Why Nature’s Cognitive Ceiling Is Not Your Ceiling

Every compound in this report exists because at some point someone decided the brain they were born with wasn’t the brain they had to keep. That decision — the fundamental premise of better than natural — is what separates the reader of this report from the majority who accept whatever cognitive performance nature assigned them.

The clinical half gives you the validated foundation. The underground half gives you the frontier. The Six Laws give you the framework to evaluate everything that comes after. Put them together and you have the most complete map of cognitive optimization currently available.

The underground does the experiment. The clinical literature confirms it years later. This report closes the gap.

Next Edition: Better Than Natural: Nootropics Field Report — July 2026

Better Than Natural is published quarterly. Science over ideology. Performance over profit.

Tony Huge holds commercial interests in Enhanced Labs and related brands. Compound rankings are editorial and not influenced by commercial relationships.